Investing at least part of the initial $1,000 in an artificial intelligence (AI) stock is a smart move. Despite impressive ...

Analysts are calling for 25% top-line growth from Intuitive Surgical this year, to be followed by 15% and 17% revenue growth ...

The stock's fall snapped a three-day winning streak.

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 9% of the investors ...

Vertex Pharmaceuticals secured European approval for Alyftrek, reinforcing its dominance in cystic fibrosis treatment as ...

Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug ...

The first new non-opioid for severe acute pain has been on the market for a few months. But it's a lot more expensive than opioids, and many people can't get it because of spotty insurance coverage.

Vertex Pharmaceuticals is currently pushing against the $467.85 resistance level as its stock maintains an upward trend.

This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...